molecules of the month

December 2020

Happy 2021! Here’s the last installment of Small Molecules of the Month for 2020. It was so hard to narrow this down to one sheet of molecules since there were so many timely publications in December. One of my favorites this month is an oral(!) ultra-long acting insulin derivative from Novo which demonstrated human efficacy in Ph. II (and yes it’s still considered a small molecule). Another interesting one is the oral non-covalent HbS modulator from Pfizer, which binds in a 2-drugs-to-1-complex fashion similar to early analogs of the covalent drug voxelotor. There were also two TNFa asymmetric trimer stabilizers from AbbVie and BMS that you shouldn’t miss, and several candidates to note for important cancer targets (CDK9, ERK, PI3Ka, PARP, ER, and IDO1). Enjoy! Also, we’re running a survey on what content would be valuable to “Drug Hunter” readers in the future. If you haven’t already, please take some time to fill out this 5 min survey. Thanks!

nominate a molecule

Encountered an interesting new molecule? Let your community know!

become a reviewer

Get sneak previews of upcoming molecules and share your knowledge and expertise with the drug discovery community.

past molecules of the month

Check out previous selections below.

molecules of the year nominees

Previous selections for Drug Hunter’s Molecule of the Year below.

hall of fame
molecules of the year

Previous selections for Drug Hunter’s Molecule of the Year below.

ask your company about a Drug Hunter membership

Member Benefits

  • Stay up-to-date and save more time with exclusive members-only content
  • On-board new team members with educational content and case studies
  • Generate ideas and discussion with easy-to-read slide decks
  • Support new content and build your industry community